GlassScriptPhysician profile
Nathaniel M Carpio
NPI 1598360042
$2,139.03
in general payments reported to CMS, 2019-2025
14 companies · $741 in 2025
The $741 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $397 · 2023: $269 · 2024: $548 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,557.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $345.59 | 2024-2025 | Yeztugo, Epclusa, Biktarvy |
| Novo Nordisk INC | $236.81 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $234.83 | 2022-2025 | Ajovy |
| Abbvie INC. | $177.02 | 2021-2023 | |
| Spr Therapeutics, INC | $133.18 | 2025 | Sprint Pns System |
| Astrazeneca Pharmaceuticals LP | $122.25 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $121.87 | 2023 | Relyvrio |
| Alnylam Pharmaceuticals INC. | $121.84 | 2024 | Amvuttra |
| Averitas Pharma INC. | $121.09 | 2023 | Qutenza |
| Mayne Pharma Commercial LLC | $119.93 | 2024 | |
| Alk-Abello, INC | $118.98 | 2025 | |
| Alkermes, INC. | $114.39 | 2025 | Vivitrol |
| Scynexis, INC. | $92.05 | 2022 | |
| Janssen Pharmaceuticals, INC | $79.20 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Carpio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.